Uzak Organ Metastazlı Akciğer Kanseri Hastalarının Değerlendirilmesi**

AMAÇ: Kanser ekonomik olarak gelişmiş ülkelerde önde gelen ölüm nedenidir ve gelişmekte olan ülkelerde ikinci önde gelen ölüm nedenidir. Çalışmanın amacı, uzak organ metastaz olan akciğer kanserli hastaların ve metastazların sağkalım oranları üzerine etkisinin değerlendirilmesidir.YÖNTEM: Uzak organ metastazı olan akciğer kanserli hastalar çalışmaya alındı. Primer tümörlerin lokalizasyonu ve metastaz, metastaz histolojik tipleri, klinik belirti ve bulgular, tümör ve lenf nodlarının etkileşimi, sağkalım oranları üzerindeki metastazların etkisi değerlendirildi.BULGULAR: Çalışmaya 174 hasta dahil edildi. Hastaların sitolojik alt gruplarının küçük hücreli dışı akciğer kanseri (KHDAK) (%75,3) ve küçük hücreli akciğer kanseri (KHAK) (%24,7) olarak iki alt gruba ayrıldı.En sık metastaz bölgleri kemik (%41,4), kontralateral akciğer (%32,8), karaciğer (%23,9) beyin (%27), böbreküstü bezi (%19,5), plevra (%9,2) idi. KHDAK ve KHAK için en sık metastaz yerleri sırasıyla kemik ve karaciğer idi. Skuamöz hücreli karsinom beyin, kemik, böbreküstü ve karşı akciğerde metastaz en yaygın türü oldu. Metastatik plevra sıvıları çoğunlukla genellikle adenokarsinom ve karaciğer metastazları ise küçük hücreli akciğer kanserlerinde kaynaklanmıştır. Kemik ve beyin ile ilgili spesifik semptomların varlığı metastaz için güçlü belirleyicilerdi.SONUÇ: Kanserin tipi, metastaz sayısı, kilo kaybı, kötü performans status, kemik ve beyin metastazı yapan KHAK'lerinde semptomların olmamasının, karaciğer metastazında ise semptomların olmasının sağkalım oranları üzerine ters etkisi vardı. Hastaların klinik laboratuvar ve radyolojik bulguları bir bütün incelenmesi metazların tahmininde faydalı olurken, gereksiz cerrahiyi önlemiş olur.AIM: Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries. The aim of the study was to evaluate distant organ metastasis in patients with lung cancer and the effect of metastasis on survival rates.METHODS: Lung cancer patients with distant organ metastasis were enrolled to the study. Localization of primary tumors and metastasis, histological types of the metastasis, clinical symptoms and signs, the interaction of tumor and lymph nodes, the effects of metastasis on survival rates were evaluated.RESULTS: 174 patients were included in the study. Cytologic subgroups of patients were subdivided as non-small cell lung cancer (NSCLC) (75.3%) and small cell lung cancer (SCLC) (24.7%). The most frequent metastatic sites were bone (41.4 %), contralateral lung (32.8%), liver (23.9%) brain (27%), adrenal gland (19,5%), pleura (9.2%). The most common metastasis sites for NSCLC and SCLC were bone and liver respectively. Squamous cell carcinoma was the most common type of metastases in brain, bone, adrenal and contralateral lung metastasis. Metastatic pleural effusions mostly originated from adenocarcinoma and liver metastasis generally originated from small cell lung cancer. Having specific symptoms related to bone and brain were powerful predictors for metastasis.CONCLUSION: Cytological types of the cancer, number of metastasis, weight loss, poor performance status, the absence of symptoms in SCLC with bone and brain metastasis, and presence of the symptoms in liver metastases had adverse effects on survival rates. Evaluation of patients with combination of clinical symptoms, laboratory and radiological findings as whole it may be helpful in predicting metastasis and may prevent unnecessary surgery

The evaluation of serum pentraxin-3 and high-sensitivity c-reactive protein levels in patients with acute attack of COPD

WOS: 000367771200014PubMed: 26882815Background: Acute exacerbations of chronic obstructive pulmonary disease (COPD) are characterized by the release of inflammatory mediators. The aim of this study was to compare serum levels of pentraxin 3 (PTX3) and high-sensitivity C-reactive protein (hs-CRP) in patients with acute exacerbations of COPD with those of a healthy control group. Methods: The study included 107 men and 19 women, with mean age of 66.5 (32 - 87) years who were diagnosed with acute COPD exacerbations and 48 healthy individuals as a control group. The serum PTX3 and hs-CRP levels were measured and pulmonary function tests were performed. Results: The mean serum level of the hs-CRP was 39.56 mg/L (10.10 - 262), and it was higher in the COPD group than in the control group (p < 0.0001). The hs-CRP levels increased in accordance with the severity of the COPD (p < 0.0001). The serum PTX3 level was 0.52 pcg/dL (0.42 - 0.56) in acute exacerbations. There was a correlation between the PTX3 levels and the pulmonary function tests, including FEV1, FVC, and FEV1/FVC (r = 0.317, p < 0.001; r = 0.385, p < 0.0001, and r = 0.248, p = 0.001, respectively). Conclusions: The short pentraxin hs-CRP is elevated in COPD patients with acute exacerbations and correlates with the severity of the disease compared with the long pentraxin PTX3. These results support the idea that hs-CRP can be used as an earlier determinant of inflammation in COPD acute exacerbations and that PTX3 cannot be used as a marker of acute exacerbation and disease severity.Ondokuz Mayis University Research FundOndokuz Mayis University [PYO. TIP.1901.11.005]This study was supported by grants from the Ondokuz Mayis University Research Fund, project number PYO. TIP.1901.11.005

Lung cancer from suspicion to treatment: An indicator of healthcare access in Turkey

Background: Lung cancer is the leading cause of cancer-related deaths worldwide. Before beginning lung cancer treatment, it is necessary to complete procedures such as suspecting lung cancer, obtaining a pathologic diagnosis, and staging. This study aimed to investigate the processes from suspicion of lung cancer to diagnosis, staging, and treatment initiation. Methods: The study was designed as a multicenter and cross-sectional study. Patients with lung cancer from various health institutions located in all geographic regions of Turkey were included in the study. The sociodemographic and clinical characteristics of the patients, the characteristics of the health institutions and geographic regions, and other variables of the lung cancer process were recorded. The time from suspicion of lung cancer to pathologic diagnosis, radiologic staging, and treatment initiation, as well as influencing factors, were investigated. Results: The study included 1410 patients from 29 different medical centers. The mean time from the initial suspicion of lung cancer to the pathologic diagnosis was 48.0 ± 52.6 days, 39.0 ± 52.7 days for radiologic staging, and 74.9 ± 65.5 days for treatment initiation. The residential areas with the most suspected lung cancer cases were highly developed socioeconomic zones. Primary healthcare services accounted for only 0.4% of patients with suspected lung cancer. The time to pathologic diagnosis was longer in the Marmara region, and the wait time for staging and treatment initiation was longer in Eastern and Southeastern Anatolia. Patients who presented to chest disease referral hospitals with peripheral lesions, those with early-stage disease, and those who were diagnosed surgically had significantly longer wait times. Conclusion: The time between pathologic diagnosis, staging, and treatment initiation in lung cancer was longer than expected. Increasing the role of primary healthcare services and distributing socioeconomic resources more equally will contribute to shortening the time to diagnosis and improve treatment processes for lung cancer